Post-dermal procedure product earns FDA approval

The Food and Drug Administration recently approved a new post-dermal procedure product developed by Oculus Innovative Sciences.

The product is intended for the removal of foreign material such as microorganisms and debris following dermal procedures.

"Within my practice I utilize the Microcyn Technology post-procedure and have been most impressed with its ability to accelerate the healing process, manage post-procedure symptoms and protect against secondary infections," said Michael Gold, MD, a board-certified dermatologist and cosmetic surgeon.

Etaluma, Calif.-based Oculus plans to launch the dermatology product in the U.S. in March 2017.

More articles on supply chain:

Hillary Clinton calls on Mylan to lower EpiPen prices
Medical device, drug recalls soar in Q2
Medical device giant Medtronic takes over HeartWare for $1.1B

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars